Concepedia

Nathan Heald

NH

Statistics

Publications

4

Citations

238

H-Index

4

Active since

2012

Affiliations

Exelixis (United States)(Current)

Nathan Heald is an author at Exelixis (United States) specializing in pharmacology, pharmacy, and hit-to-lead optimization.

Publications per year

2012–2015

4

Publications

4

<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 130 citations · Full text

, , +16

Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors

James W. Leahy, Chris A. Buhr, Henry W. B. Johnson et al. · Journal of Medicinal Chemistry · 2012 · 47 citations · Full text

, , +13

Quantitative Assessment of Antibody Internalization with Novel Monoclonal Antibodies against Alexa Fluorophores

Sindy Liao-Chan, Barbara Daine-Matsuoka, Nathan Heald et al. · PLoS ONE · 2015 · 40 citations · Full text

, , +17

Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists

Mohamed A. Ibrahim, Henry W. B. Johnson, Joon Won Jeong et al. · Journal of Medicinal Chemistry · 2012 · 21 citations · Full text

, , +13

1–4 of 4